<DOC>
	<DOCNO>NCT01250171</DOCNO>
	<brief_summary>This study assess effect single intravenous dose secukinumab ( AIN457 ) 10 mg/kg canakinumab ( ACZ885 ) 10 mg/kg sign symptom dry eye . In addition , pharmacokinetic , pharmacodynamic , safety profile secukinumab canakinumab assess . Blood sample collect analysis effect secukinumab canakinumab select biomarkers .</brief_summary>
	<brief_title>The Effects Single Intravenous Administration Secukinumab ( AIN457 ) Canakinumab ( ACZ885 ) Dry Eye Patients</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient age 1885 diagnosis moderate severe dry eye . Schirmer test without anesthesia ≥ 1 &lt; 10 mm wet 5 minute least 1 eye . Tear break time &lt; 7 second least 1 eye . Corneal stain score ≥ 3 ( National Eye Institute [ NEI ] grade scale ) . Conjunctival redness ≥ 1 . Ocular surface disease index modest severe . Ability provide inform consent . Pregnant breastfeed woman . Hemoglobin &lt; 10 g/dl . Total white blood count ( WBC ) outside range 300014,000/µl . Platelets &lt; 100,000/µl . Use ocular , periocular , systemic steroid within 60 day prior screen . Use contact lenses prior corneal refractive surgery either eye . Requirement eye drop use study . Anesthetic neurotrophic cornea . Temporary punctal plug . Recent planned exposure live vaccination . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>IL17/ IL-1β</keyword>
	<keyword>Biologic</keyword>
</DOC>